Prednisone plus Gefitinib versus Prednisone plus Placebo in the Treatment of Hormone-Refractory Prostate Cancer: A Randomized Phase II Trial

Publisher： Karger

E-ISSN： 1423-0232|74|3-4|223-228

ISSN： 0030-2414

Source： Oncology, Vol.74, Iss.3-4, 2008-08, pp. : 223-228

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer

By  

Oncology, Vol. 68, Iss. 1, 2005-04 ,pp. : 2-9

Karger

Access to resources Recommend Favorite

Docetaxel plus Prednisone versus Mitoxantrone plus Prednisone for Metastatic Hormone-Refractory Prostate Cancer in Chinese Patients: Experience of a Single Center

By  

Urologia Internationalis, Vol. 79, Iss. 4, 2007-11 ,pp. : 307-311

Karger

Access to resources Recommend Favorite

An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer

By  

Oncology Research and Treatment, Vol. 30, Iss. 7, 2007-06 ,pp. : 355-360

Karger

Access to resources Recommend Favorite

Phase II Trial of Copper Depletion with Tetrathiomolybdate as an Antiangiogenesis Strategy in Patients with Hormone-Refractory Prostate Cancer

By  

Oncology, Vol. 71, Iss. 3-4, 2007-07 ,pp. : 168-175

Karger

Access to resources Recommend Favorite

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

By  

Oncology, Vol. 73, Iss. 1-2, 2008-03 ,pp. : 9-20

Karger

Access to resources Recommend Favorite